Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 (STAT1) gain-of-function mutation

Katja G. Weinacht, MD, PhD,a,b* Louis-Marie Charbonnier, PhD,c Louis Marie Charbonnier, PhD,c* Fayhan Alroqi, MD,§ Ashley Plant, MD,a,b Qi Qiao, PhD,d Hao Wu, PhD,d,c,e Clement Ma, PhD,a,b Troy R. Torgerson, MD, PhD,d,e Sergio D. Rosenzweig, MD, PhD,a,h Thomas A. Fleisher, MD,b Luigi D. Notarangelo, MD,c,§ Imelda C. Hanson, MD,§ Lisa R. Forbes, MD,§ and Talal A. Chatila, MD, MS

Graphical Abstract

Background: Gain-of-function (GOF) mutations in the human signal transducer and activator of transcription 1 (STAT1) manifest in immunodeficiency and autoimmunity with impaired T<sub>H</sub>17 cell differentiation and exaggerated responsiveness to type I and II interferons. Allogeneic bone marrow transplantation has been attempted in severely affected patients, but outcomes have been poor.

Objective: We sought to define the effect of increased STAT1 activity on T helper cell polarization and to investigate the therapeutic potential of ruxolitinib in treating autoimmunity secondary to STAT1 GOF mutations.

Methods: We used in vitro polarization assays, as well as phenotypic and functional analysis of STAT1-mutated patient cells.

Results: We report a child with a novel mutation in the linker domain of STAT1 who had life-threatening autoimmune cytopenias and chronic mucocutaneous candidiasis. Naive lymphocytes from the affected patient displayed increased T<sub>H</sub>1 and follicular T helper cell and suppressed T<sub>H</sub>17 cell responses. The mutation augmented cytokine-induced STAT1 phosphorylation without affecting dephosphorylation kinetics. Treatment with the Janus kinase 1/2 inhibitor from the Division of Hematology/Oncology, the Division of Immunology, and the Program in Molecular and Cellular Medicine, Boston Children’s Hospital, Department of Pediatrics, Harvard Medical School, Boston; the Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston; the Department of Immunology, Seattle Children’s Hospital; the Department of Pediatrics, Immunology Division, University of Washington, Seattle; the Primary Immunodeficiency Clinic, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda; the Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda; Harvard Stem Cell Institute, Cambridge; and Baylor College of Medicine and Texas Children’s Hospital, Department of Pediatrics, Section of Immunology, Allergy and Rheumatology and Center for Human Immunobiology, Houston.

Support: National Institutes of Health grants R01AI085090 and 1R56AI115699. "These authors contributed equally to this work. K. G. Weinacht, MD, PhD, is currently affiliated with the Division of Stem Cell Transplantation and Regenerative Medicine, Lucile Packard Children’s Hospital, Stanford School of Medicine, Stanford, Calif. Supported by National Institutes of Health grants R01AI085090 and 1R56AI115699 (to T.A.C.). Disclosure of potential conflict of interest: K. G. Weinacht’s institution has received grants from the National Institutes of Health (NIH) and National Institute of Allergy and Infectious Diseases (NIAID). T. R. Torgerson has received consulting fees from Baxalta Biosciences, CSL Behring, and ADMA Biosciences and payment for developments of educational presentations from Baxalta Biosciences, CSL Behring, and RWJF, and his institution has received grants from Baxalta Biosciences, CSL Behring, and NIH. T. A. Fleisher is employed by the NIH; has received board membership from the American Academy of Allergy, Asthma & Immunology (AAAAI); received payment for lectures from the Louisiana Allergy, Asthma and Immunology Society and Alaska Allergy, Asthma and Immunology Society; and received royalties from Elsevier. L. D. Notarangelo has received board membership from Novimmune and consultancy fees from Sigma-Tau; is employed by Boston Children’s Hospital; and has received royalties from UpToDate, and his institution has received grants from the NIH and March of Dimes. L. R. Forbes’s institution has received grants from a Chao Physician–Scientist grant from Baylor College of Medicine. T. A. Chatila’s institution has received grants R01AI085090 and 1R56AI115699 from the NIH. The rest of the authors declare that they have no relevant conflicts of interest. Received for publication March 5, 2016; revised October 18, 2016; accepted for publication November 2, 2016. Corresponding author: Katja G. Weinacht, MD, PhD, Division of Stem Cell Transplantation and Regenerative Medicine, Stanford School of Medicine, 300 Pasteur Dr, H3320, Stanford, CA 94305. E-mail: kgw1@stanford.edu.

© 2016 American Academy of Allergy, Asthma & Immunology http://dx.doi.org/10.1016/j.jaci.2016.11.022
ruxolitinib reduced hyperresponsiveness to type I and II interferons, normalized T<sub>H</sub>1 and follicular T helper cell responses, improved T<sub>H</sub>17 differentiation, cured mucocutaneous candidiasis, and maintained remission of immune-mediated cytopenias.

Conclusions: Autoimmunity and infection caused by STAT1 GOF mutations are the result of dysregulated T helper cell responses. Janus kinase inhibitor therapy could represent an effective targeted treatment for long-term disease control in severely affected patients for whom hematopoietic stem cell transplantation is not available. (J Allergy Clin Immunol 2017;nnn:nnn-nnn.)

Key words: STAT1 gain of function, IFN-γ, ruxolitinib, autoimmunity, T<sub>H</sub>1 cell, T<sub>H</sub>17 cell, follicular T helper cell, T helper cell polarization

Signal transducer and activator of transcription 1 (STAT1) is a member of the STAT family of transcription factors which play a key role in the cellular response to interferons and is a central component in many other signaling pathways, including interleukins, growth factors, and hormones. In response to extracellular receptor stimulation, Janus kinase (JAK) activation leads to phosphorylation of cytoplasmic STAT1, followed by homodimerization or heterodimerization with other phosphorylated STAT family members. The dimers translocate into the nucleus and bind designated promoter elements to activate transcription of their respective target genes.1-3

STAT1 is the target of both loss-of-function and gain-of-function (GOF) mutations. Whereas the former are associated with susceptibility to mycobacterial and/or viral infections, the latter give rise to a mixed phenotype of autoimmunity, mucocutaneous candidiasis, and invasive fungal infections related to augmented T<sub>H</sub>1 and diminished T<sub>H</sub>17 cell responses.4-9 STAT1 GOF mutations prompt a signal-induced increase in levels of phosphorylated STAT1 (phospho-STAT) and amplified transcription of interferon-responsive genes, which lead to autoimmunity.5,6,10 Delayed dephosphorylation with ensuing accumulation of phospho-STAT1 in the nucleus has been proposed as a mechanistic basis in most reported cases.1,6,11-15 How increased STAT1 activity compromises T<sub>H</sub>17 immunity to result in chronic mucocutaneous candidiasis and other invasive fungal and viral infections is less well understood.12,16,17 Excessive production of interferons, IL-27, and programmed death (PD) 1 ligand can directly impair T<sub>H</sub>17 cell differentiation.18,19 Alternatively, predominance of STAT1 signaling over STAT3 signaling might deviate the response to IL-6, IL-21, and IL-23 away from STAT3, which normally mediates T<sub>H</sub>17 cell development.20

The clinical management of patients with STAT1 GOF mutations remains challenging.21-23 In particular, controlling autoimmunity is difficult because conventional immunosuppression adds to the already increased risk of infections. Therapy-refractory or life-threatening disease is considered a noncanonical indication for allogeneic hematopoietic cell transplantation; however, the immune phenotype of STAT1 GOF mutations amplifies the transplant-related risk for uncontrolled infections and graft-versus-host disease, contributing further to the poor prognosis.21,23

Liu et al24 were the first to provide proof of principle that JAK inhibitors can successfully treat STAT1-mediated hyperresponsiveness to interferons in patients with vascular and pulmonary syndrome caused by mutations in TMEM173, which encodes the stimulator of interferon genes. Higgins et al25 reported hair regrowth in a patient with alopecia areata secondary to a STAT1 GOF mutation after treatment with ruxolitinib. Most recently, Mösner et al26 observed improvement of chronic mucocutaneous candidiasis with ruxolitinib and a reactive increase in IL-17A/F levels.

Here we describe the immunophenotypic analysis of a patient with life-threatening autoimmune cytopenias and a novel GOF mutation in the linker domain of STAT1. Importantly, in addition to increasing T<sub>H</sub>1 and suppressing T<sub>H</sub>17 cell differentiation, the augmented STAT1 activity dysregulated follicular T helper (T<sub>FH</sub>) cell responses. This finding was corroborated in a different patient with known STAT1<sup>T385SM</sup> GOF mutation in the DNA-binding domain who presented solely with chronic mucocutaneous candidiasis and opportunistic infections but without clinical evidence of autoimmunity.13,26,27 Long-term treatment with the JAK inhibitor ruxolitinib decreased the increased STAT1 phosphorylation, reversed the dysregulated T<sub>H</sub>1 and T<sub>FH</sub> cell development, improved the previously impaired T<sub>H</sub>17 response, and enabled effective control of the autoimmune cytopenias. This is the first report demonstrating mechanistic evidence that pharmacologic manipulation of the JAK-STAT pathway in patients with STAT1 GOF mutations leads to reversal of the immune dysregulation phenotype and provides proof of principle that JAK inhibitors are not only effective in treating active autoimmune disease and immunodeficiency secondary to hyperresponsiveness of STAT1 but also in reversing the aberrant priming of naïve cells, thereby maintaining long-term disease control and sustained remission.

METHODS
Patients and healthy subjects
All study participants were recruited after obtaining written informed consent approved by the Boston Children’s Hospital Institutional Review Board.

Pharmacotherapy
The IL-1 receptor antagonist anakinra (Kineret; Sobi, Stockholm, Sweden) was administered intravenously twice daily at a dose of 100 mg.

Four infusions with equine anti-thymocyte globulin (ATG; Atgam; Pfizer, New York, NY) were administered intravenously at a dose of 40 mg/kg body weight per infusion 24 hours apart. Supportive therapy during the infusions consisted of acetaminophen, diphenhydramine, and methylprednisolone.

Treatment with intravenous cyclosporine (Sandimmune: Novartis, East Hanover, NJ) was initiated on day 1 of ATG therapy at a dose of 4 mg/kg body
weight per day and titrated to a serum level of 175 to 250 µg/L. The route of administration was converted to oral after 4 weeks, maintaining the same serum target level.

Eculizumab (Soliris; Alexion Pharmaceuticals, Cheshire, Conn) was administered intravenously at a dose of 600 mg per infusion. Only 1 infusion was administered because of a lack of efficacy. Supportive therapy during the infusion consisted of acetaminophen, diphenhydramine, and methylprednisolone. The patient received a meningococcal vaccination prior to treatment with eculizumab, as well as meningococcal prophylaxis with azithromycin for 6 months after infusion.

Rituximab (Rituxan; Genentech, South San Francisco, Calif) was administered intravenously at a dose of 375 mg/m² body surface area (BSA) once weekly for 4 consecutive weeks. Supportive therapy during the infusions consisted of acetaminophen, diphenhydramine, and methylprednisolone.

Treatment with ruxolitinib (Jakafi; Incyte, Wilmington, Del) was initiated at a low dose of 5 mg/m² BSA once daily because of concomitant use of other CYP3A4-inhibiting medications. The ruxolitinib dose was escalated until the amount of phospho-STAT1 induced in the patient’s CD4⁺ T cells was equal to that in healthy control cells. The final therapeutic ruxolitinib dose was 10 mg/m² BSA per day administered orally in 2 divided doses.

**STAT1 sequencing**
Exons 3 to 23 of STAT1, including exon/intron boundaries, were amplified from genomic DNA by means of PCR and sequenced bidirectionally with dye-terminator chemistry. PCR amplification of exon 20 was carried out with the following primers: STAT1E20_F (GATAAGAGCGGGGAGGG) and STAT1E20_R (TGAAGCTGGACTCAGGC). The mutation was predicted to be deleterious by using SIFT and PolyPhen-2.

**Protein modeling**
The STAT1E545K mutant structure was generated by using SWISS-MODEL with STAT1 structures (PDB code: 1YVL and 1BF5). Structural alignment was performed in Coot, and molecular representation was displayed in PyMOL.

**Antibodies and flow cytometry**
Monoclonal antibodies to the following human proteins were used for staining: CD3 (UCHT1), CD4 (RPA-T4), CD8 (RPA-T8), CD45RA (HI100), CCR7 (G043H7), inducible costimulator (ICOS; C398.4A), PD1 (eBioJ105), CXCR5 (MU5UBEE), phospho-STAT1 (KIKSI0803), and phospho-STAT3 (LUVNKL; all from eBioscience, San Diego, Calif); IL-12 (20 ng/mL; PeproTech, Rocky Hills, NJ); IFN-γ (20 ng/mL; Miltenyi Biotec), IFN-γ, or IL-21 (20 ng/mL, PeproTech).

**T helper cell subset differentiation**
CD4⁺ T cells were enriched from PBMCs by means of negative selection with magnetic beads (Miltenyi Biotec), and naive CD45RA⁺CCR7⁺CD4⁺ T cells were then isolated by means of cell sorting with a BD FACSaria cytometer. Naive CD4⁺ T cells were seeded at a concentration of 5 × 10⁵ cells per well in a 96-well plate in complete medium and stimulated with anti-CD2/CD3/CD28 beads (Miltenyi Biotec) alone (T0 condition) or in the presence of recombinant human cytokines: IL-12 (20 ng/mL) for T17 conditions (BioLegend); IL-6 (20 ng/mL), IL-23 (10 ng/mL; both from BioLegend), and TGF-β1 (5 ng/mL; R&D Systems) for T17 conditions; and IL-12 (2 ng/mL), IL-23 (10 ng/mL), and TGF-β1 (5 ng/mL) for T19 conditions.

**Statistical analysis**
Comparisons between the patient and healthy control subjects were analyzed by using the unpaired Student t test and 1- or 2-way ANOVA with posttest analysis. Two-sided P values of less than .05 were considered statistically significant.

**RESULTS**
**Refractory autoimmune cytopenias associated with a novel STAT1 GOF mutation**
A 10-year-old girl with a longstanding history of Evans syndrome manifesting in autoimmune hemolytic anemia and immune thrombocytopenia presented to our institution with an acute exacerbation of her disease (in the following referred to as “the” patient or patient 1). She required daily packed red blood cell transfusions to keep her hemoglobin level at greater than 6 g/dL and experienced systemic bleeding symptoms refractory to platelet transfusion. At presentation, the patient had already been treated with a prolonged course of steroids and multiple doses of intravenous immunoglobulins. Although these therapies did not induce remission, withdrawal of steroids spurred the rate of hemolysis further, necessitating continued glucocorticoid therapy.

The patient had a history of chronic mucocutaneous candidiasis involving her nails, oral mucosa, and vaginal tract. She also had chronic diarrhea and severe chronic lung disease with respiratory insufficiency requiring supplemental oxygen. She was a poor responder to vaccines and had been treated with immunoglobulin replacement over extended periods of her life. The parents were nonconsanguineous, and there was no family history of anti-CD2/CD3/CD28 beads (Miltenyi Biotec) and 100 U/mL recombinant human IL-2 (PeproTech) for 2 days. Subsequently, cell suspensions were incubated with phorbol 12-myristate 13-acetate (50 ng/mL; Sigma-Aldrich, St Louis, Mo), ionomycin (500 ng/mL; Sigma-Aldrich), and GolgiPlug (BD Biosciences, San Jose, Calif), according to the manufacturer’s instructions, in complete medium for 4 hours before surface staining. Permeabilization and intracellular IFN-γ and IL-17 staining were carried out with an eBioscience Fixation/Permeabilization kit, as described above. Data were collected with an LSRFortessa cytometer (BD Biosciences) and analyzed with FlowJo software (TreeStar, Ashland, Ore).
autoimmunity, immunodeficiency, or other blood dyscrasias. HLA typing revealed that the patient’s only sibling was not a match.

A comprehensive diagnostic evaluation revealed positive antiplatelet IgM antibody levels, as well as a complement-fixing, high-affinity, high-thermal-amplitude cold agglutinin. Consequently, the patient received a course of the anti-CD20 mAb rituximab followed by the anti-complement C5 antibody eculizumab without clinical improvement. Over the course of the following 6 weeks, the patient’s reticulocyte count and absolute neutrophil count started to decrease, whereas ferritin and lactate dehydrogenase levels were increasing. Serial bone marrow biopsies demonstrated a steady decrease in bone marrow cellularity from greater than 70% before admission to less than 10% 11 weeks later, leading to the diagnosis of acquired aplastic anemia. A bone marrow aspirate also revealed occasional CD163+ hemophagocytic histiocytes, for which treatment with the IL-1 receptor antagonist anakinra for presumed macrophage activation syndrome was added to the baseline steroid therapy.

A diagnostic workup for genetic causes of bone marrow failure was nonrevealing. Accordingly, the patient received standard immunosuppressive therapy for idiopathic aplastic anemia.

**FIG 1.** Hemoglobin and platelet count in response to pharmacotherapy. The graph depicts serum hemoglobin concentration in grams per deciliter (gray curve) and platelet count in $10^9$ cells per microliter (black curve) in response to changes in steroid dose, as well as pharmacotherapy with ATG, the IL-1 receptor antagonist anakinra, cyclosporine, and ruxolitinib. Timing of packed red blood cell transfusions is indicated in dark gray. The prednisone dose is expressed in milligrams per kilogram body weight.
without an available matched sibling donor consisting of 4 doses of equine ATG and cyclosporine. Although the initial posttreatment course was complicated by intraventricular hemorrhage and acute respiratory decompensation, over the following 8-week period, the patient’s clinical course stabilized. The absolute neutrophil and reticulocyte counts began to increase, which is consistent with bone marrow recovery in response to treatment with ATG and cyclosporine. However, hemolysis started to flare, and hemoglobin levels rapidly decreased again as soon as steroids were weaned, indicating that ATG and cyclosporine successfully treated the patient’s aplastic anemia but did not bring the autoimmune cytopenias into complete remission (Fig 1 and see Fig E1 in this article’s Online Repository at www.jacionline.org). Together with the development of acute steroid-induced diabetes, the need for an alternate therapy to control the persisting autoimmune cytopenias became critical.

Unbiased genetic testing for 200 known/selected inborn errors of immunity identified a monoallelic \textit{de novo} missense mutation in the coding region of \textit{STAT1} that resulted in an amino acid substitution in the linker domain of the protein and was predicted to be deleterious by using SIFT and PolyPhen-2 (c.1633G>A; p.E545K; Fig 2, A and B). Structure modeling revealed that the E545 residue is far away from the previously proposed STAT1 dimerization interface but close to the SH2 domain, which binds the activating IFN-\gamma receptor peptide, suggesting that this mutation might affect STAT dimer binding to cytokine receptors or kinases. This mutation did not affect expression of total STAT1 protein in CD4\(^+\) and CD8\(^+\) T cells or in B cells at baseline (Fig 2, C, and data not shown). However, on stimulation of PBMCs with IFN-\(\beta\) (20 ng/mL) or IFN-\(\gamma\) (20 ng/mL) the patient’s CD4\(^+\) T cells demonstrated a significant increase in STAT1 phosphorylation compared with that seen in control cells (Fig 2, D). Unlike other reported \textit{STAT1} GOF mutations, the E545K mutation did not affect the dephosphorylation kinetics on cytokine deprivation, which led to normalization of phospho-STAT1 expression down to baseline levels in cells
from the patient and control subjects over the same amount of time (Fig 2, E). Similar results were found on stimulation and withdrawal of the patient’s CD8+ T cells with the respective interferon (data not shown). These results suggest that the E545K mutation is an atypical STAT1 GOF mutation leading to hyperphosphorylation of STAT1 in response to type I and II interferons without interfering with the dephosphorylation process.

**STAT1<sup>E545K</sup>** mediates exaggerated Th1/cytotoxic T type 1 (Tc1) skewing and suppresses Th17 cell differentiation

Examination of PBMCs 6 months after ATG and rituximab therapy revealed that the patient had a higher proportion of IFN-γ-producing and lower proportion of IL-17–producing circulating CD4+ and CD8+ T cells compared with healthy control subjects (Fig 3, A and B). To gain insight into the link between the **STAT1<sup>E545K</sup>** mutation and the patient’s clinical presentation with autoimmunity, we evaluated the number of TFH cells, which were defined as CD4+ CXCR5+ PD1+ cells (Fig 3, C). The patient’s CD4+ T cells showed an approximately 7-fold increase in the fraction of CXCR5+PD1+ T cells compared with healthy control cells (Fig 3, C), which is suggestive of an increased risk of dysregulated humoral immunity conferred by the **STAT1<sup>E545K</sup>** mutation.

To corroborate the hypothesis that dysregulated T<sub>FH</sub> cell immunity is a primary feature of amplified STAT1 activity, we selected a second patient (patient 2) with a different **STAT1<sup>T385M</sup>** mutation (Fig 3, D). The patient’s CD4+ T cells showed an approximately 7-fold increase in the fraction of CXCR5+PD1+ T cells compared with healthy control cells (Fig 3, D), which is suggestive of an increased risk of dysregulated humoral immunity conferred by the **STAT1<sup>E545K</sup>** mutation.
mutation, which is known to confer GOF activity based on previous reports in the literature.13,26,27 As expected, CD4\(^+\) T cells from patient 2 displayed exaggerated STAT1-phosphorylation in response to \textit{in vitro} stimulation with type I and II interferons, which could also be mitigated by \textit{in vitro} treatment with ruxolitinib (see Fig E2 in this article’s Online Repository at www.jacionline.org). Importantly, patient 2 had chronic mucocutaneous candidiasis and opportunistic infectious without any clinical evidence of autoimmunity and had an increase in the fraction of circulating CXCR5\(^+\)PD1\(^+\) TFH cells (Fig 3, C). The TFH cells of both patient 1 and patient 2 exhibited high expression of the pro-T\(_{H1}\) chemokine receptor CXCR3 and decreased expression of the pro-T\(_{H17}\) chemokine receptor CCR6, which is in agreement with previous studies (Fig 3, D).37,38

The JAK1/2 inhibitor ruxolitinib suppresses dysregulated STAT1\(^{E545K}\) phosphorylation induced by interferons

The JAK inhibitors ruxolitinib and tofacitinib, which primarily target JAK1/2 and JAK3, respectively, have been used to target dysregulated JAK/STAT activity in patients with different clinical conditions.10,24 To investigate which of these 2 JAK inhibitors is most specific in normalizing STAT1\(^{E545K}\) activity without interfering with STAT3 signaling relevant to T\(_{H17}\) differentiation, we tested the effects of ruxolitinib and tofacitinib on STAT1 and STAT3 activation in response to IFN-\(\beta\) and IFN-\(\gamma\) or IL-21 stimulation, respectively. Both drugs suppressed STAT1 and STAT3 phosphorylation in CD4\(^+\) T cells from patient 1 and control subjects in a concentration-dependent manner. Ruxolitinib was more selective in suppressing STAT1 phosphorylation in

---

**FIG 4.** Different JAK inhibitors variably inhibit STAT1 and STAT3 phosphorylation \textit{in vitro}. 

\textbf{A,} Phospho-STAT1 (P-STAT1) expression on IFN-\(\beta\) stimulation in CD4\(^+\) T cells from a control subject and the STAT1\(^{E545K}\) patient treated \textit{in vitro} with 10 and 100 nmol/L concentrations of ruxolitinib (red curve) and tofacitinib (blue curve) or vehicle (dimethyl sulfoxide, black curve). Plain gray corresponds to unstimulated cells. **B,** Phospho-STAT1 mean fluorescence intensity (MFI) expressed as percentage of maximum vehicle-treated control CD4\(^+\) T cells shown in Fig 4, A. Phospho-STAT1 expression on IL-21 stimulation in CD4\(^+\) T cells from a control subject and the STAT1\(^{E545K}\) patient treated \textit{in vitro} with 10 and 100 nmol/L concentrations of ruxolitinib (red curve) and tofacitinib (blue curve) or vehicle. Plain gray corresponds to unstimulated cells. **C,** Phospho-STAT3 mean fluorescence intensity (MFI) expressed as a percentage of maximum vehicle-treated control CD4\(^+\) T cells shown in Fig 4, C. **P** < .001 and ***P** < .0001, 2-way ANOVA with posttest analysis.
response to IFN-β stimulation compared with tofacitinib, which is reflective of a lesser half-maximal inhibitory concentration (IC₅₀) necessary to block JAK1/2 activation (Fig 4, A). In contrast, ruxolitinib was more sparing toward STAT3 phosphorylation in response to IL-21 stimulation, which is reflective of its higher IC₅₀ toward JAK3 compared with tofacitinib (Fig 4, B). Optimal effects were achieved with ruxolitinib at a concentration of 10 nmol/L, which decreased the STAT1 phosphorylation in the patient’s CD4⁺ T cells from more than 400% before treatment to approximately 150% of the STAT1 activity in vehicle-treated control CD4⁺ T cells (Fig 4, C). The suppressive effect of tofacitinib on STAT1 and STAT3 phosphorylation in CD4⁺ T cells from control subjects and the patient in response to IFN-β and IL-21 stimulation was dose dependent but nonselective with equal IC₅₀ values for STAT1 and STAT3, making it less suitable to treat isolated STAT1 hyperreactivity (Fig 4).

**JAK inhibitor treatment controls STAT1 phosphorylation**

Based on these in vitro data, we started treating the STAT1E₅₄₅₉K patient (patient 1) with ruxolitinib. We adjusted the ruxolitinib treatment dose in the patient so that STAT1 phosphorylation in response to stimulation with IFN-β and IFN-γ in the patient’s CD4⁺ T cells decreased to approximately 100% relative to that in control CD4⁺ T cells (Fig 5, A and B). At this dose, which is equivalent to 10 mg/m² BSA per day, the patient’s STAT3 phosphorylation in CD4⁺ T cells in response to IL-21 stimulation was maintained at greater than 80% relative to that in control CD4⁺ T cells, matching our in vitro findings (Fig 5, C and D).

**Ruxolitinib treatment normalizes amplified TH1 and improves impaired TH17 responses**

After 3 to 4 months of ruxolitinib therapy at the target dose, the IFN-γ production in circulating CD4⁺ T cells from the patient decreased significantly, whereas IL-17 production in circulating CD4⁺ T cells initially remained low despite clinical improvement in mucocutaneous candidiasis and diarrhea. After more than 1 year of therapy with ruxolitinib and after discontinuation of all other immunosuppressive medications, IFN-γ production in CD4⁺ T cells from the STAT1E₅₄₅₉K patient remained suppressed to the level seen in normal control cells, whereas IL-17 production increased along with consolidation of the clinical picture (Fig 6, A and B). To assess whether ruxolitinib also has an effect on the aberrant priming of undifferentiated cells, we investigated the

---

**FIG 5. In vivo ruxolitinib treatment differentially controls STAT1 phosphorylation.**

A, Expression of phospho-STAT1 (P-STAT1) in CD4⁺ T cells of the STAT1E₅₄₅₉K patient and control subject before and after in vivo therapy with ruxolitinib after IFN-β stimulation. B, Histogram represents phospho-STAT1 mean fluorescence intensity (MFI) normalized to expression in control CD4⁺ T cells after IFN-β or IFN-γ stimulation before and after in vivo therapy with ruxolitinib. C, Expression of phospho-STAT3 in CD4⁺ T cells of the STAT1E₅₄₅₉K patient and control subject before and after in vivo therapy with ruxolitinib after IL-21 stimulation. D, Histogram represents phospho-STAT3 MFI normalized to expression in control CD4⁺ T cells after IL-21 stimulation before and after in vivo therapy with ruxolitinib. *P < .05 and ***P < .001.
capacity of naive CD4+ T cells from patient 1 to polarize into IFN-γ- or IL-17-producing T_{H1} or T_{H17} cells, respectively, by means of in vitro differentiation under T_{H0} (anti-CD2/CD3/28), T_{H1} (anti-CD2/CD3/28 and IL-12), and T_{H17} (anti-CD2/CD3/28, IL-6, IL-23, and TGF-β1) conditions (Fig 6, C and D). Our results revealed that the patient’s naive CD4+ T cells were biased to adopt a T_{H1} fate with marked skewing toward IFN-γ production under all 3 conditions compared with control T cells. In contrast, IL-17 production was suppressed, especially under T_{H17}-polarizing conditions. Importantly, the priming of the STAT1^{E545K} mutation toward a T_{H1}/T_{H1} phenotype and antagonizing T_{H17} differentiation was almost entirely reversible with long-term treatment (>12 months) of the patient with ruxolitinib. No further drug was added to the in vitro culture conditions.

**Ruxolitinib maintenance therapy reverses dysregulated T_{FH} cell expansion associated with the STAT1^{E545K} mutation**

To investigate whether ruxolitinib is also effective in controlling the augmented T_{FH} response and possible T_{FH} priming caused by STAT1^{E545K}, we assessed the in vitro differentiation capacity of naive CD4+ T cells from patient 1 into T_{FH} cells with TGF-β1, IL-12, and IL-23 before treatment with ruxolitinib and at multiple time points after (3 months, 12 months, and thereafter). After only 3 months of ruxolitinib at the target dose, numbers of circulating T_{FH} cells in the STAT1^{E545K} patient normalized down to control levels (Fig 7, A and B) and remained stable over 12 months thereafter (data not shown).

To generate evidence that the enlarged T_{FH} compartment is a primary phenotype of the STAT1^{E545K} mutation and not a...
consequence of the longstanding history of autoimmune disease in our patient, we performed in vitro polarization studies showing that naive CD4+ T cells from patient 1 had a profoundly exaggerated response to stimulation with TGF-β1, IL-12, and IL-23 compared with control cells, which led to the development of an expanded population of CXCR5+ICOS+ TFH-like cells with higher ICOS expression levels. Ruxolitinib inhibited in vitro TFH cell development in response to TGF-β1, IL-12, and IL-23, leading to a number of CXCR5+ICOS+ TFH-like cells in the patient with the STAT1E545K mutation that was comparable with that in control subjects before treatment (Fig 7, C-E).

DISCUSSION

In this report we describe that a patient with a novel STAT1E545K GOF mutation in the linker domain, which is associated with increased STAT1 phosphorylation, immune dysregulation, and intractable life-threatening autoimmune cytopenias, favorably responded to therapy with ruxolitinib. Long-term therapy addressed all immunophenotypic features of the disease, including cytokine-induced STAT1 hyperphosphorylation, amplified TTH1 and TFH cell differentiation, impaired TTH17 immunity, and the respective aberrant priming of naive cells. Ruxolitinib controlled the autoimmune cytopenias, cured mucocutaneous candidiasis and diarrhea, led to a gradual amelioration of pulmonary function (forced vital capacity was 90% and FEV1 was 80% after ruxolitinib treatment, compared with a forced vital capacity of 75% and FEV1 of 66% prior to initiation of therapy), and allowed us to wean the patient off all other immunosuppressive therapy. Initial concerns that ruxolitinib could cause JAK2-mediated dose-limiting myelosuppression and anemia proved unsubstantiated. Thus JAK inhibitor therapy represents a rational

**FIG 7.** Ruxolitinib treatment corrects the exacerbated TFH response in the STAT1E545K patient. A, CXCR5 and PD1 expression in CD4+ T cells in the STAT1E545K patient before and after treatment with ruxolitinib at target dose for 3 months compared with control subjects. B, Histograms represent frequencies of TFH cells in the STAT1E545K patient before and after treatment compared with control subjects. C, CXCR5 and ICOS expression in in vitro–differentiated TFH-like cells from the patient and control subjects stimulated with TGF-β1, IL-12, and IL-23 in the presence or absence of ruxolitinib. D, Histograms represent frequencies of in vitro–differentiated TFH cells with and without ruxolitinib in the patient and control subjects. E, ICOS mean fluorescence intensity (MFI) in in vitro–differentiated TFH cells with and without ruxolitinib in the patient and control subjects. **P < .01 and ***P < .001, 1-way (Fig 7, B, D, and E) and 2-way (Fig 7, D and E) ANOVA with posttest analysis.
and effective therapy in patients with this disease. As with all immunomodulatory and immunosuppressive medications, careful clinical surveillance for side effects, including serious infections and malignancy, is warranted.

Like other STAT1 GOF mutations, the STAT1<sup>E545K</sup> mutation augmented STAT1 phosphorylation in response to cytokine signaling. However, unlike other common STAT1 GOF mutations, it potentiated STAT1 phosphorylation without affecting dephosphorylation after withdrawal of the activating cytokine. Also, it did not perturb the basal levels of phospho-STAT1 absent cytokine stimulation, suggesting that it promoted increased recruitment of STAT1 at the respective cytokine receptor. Of note, STAT3 phosphorylation was normal.

The STAT1<sup>E545K</sup> mutation augmented the in vitro polarization of naive CD4<sup>+</sup> T cells into Th1 and Tfh cell subsets while rendering them resistant to Th17 polarization. Similar skewing of helper T cell subsets was also observed in vivo, with the patient showing increased Th1 and Tfh but decreased Th17 cell counts in the circulation. Suppressed Th17 differentiation was noted despite normal STAT3 phosphorylation. Our findings are consistent with those of recent studies demonstrating that STAT1 GOF mutations act distally to suppress STAT3 activation of components of the Th17 transcriptional program, including RORC, without affecting cytokine-mediated STAT3 phosphorylation. Surprisingly, the STAT1<sup>E545K</sup> mutation was associated with a markedly expanded pool of circulating Tfh cells. Similar observations were made in a patient (patient 2) with a different STAT1 GOF mutation affecting the DNA-binding domain who was clinically free from any signs of autoimmunity. These findings suggest that a dysregulated Tfh cell response is a primary feature of increased STAT1 activity independent of and not secondary to clinical autoimmunity. The molecular mechanisms leading to this enlarged Tfh cell compartment are not clear. Tfh cell expansion has been associated with humoral autoimmunity, and several monogenic immune dysregulatory diseases with humoral autoimmunity are associated with an expanded Tfh cell pool, including cytotoxic T lymphocyte–associated antigen 4 and LPS-responsive beige-like anchor protein deficiency.

By decreasing STAT1 hyperphosphorylation, JAK inhibitors break the sequence of unopposed interferon release, normalize Th1 and Tfh cell responses, and treat autoimmunity. In our studies long-term JAK inhibitor treatment also promoted Th17 differentiation of naive CD4<sup>+</sup> T cells in vitro and rescued IL-17 production in vivo, which was clinically reflected by a significant improvement in mucosal immunity under ruxolitinib therapy. This is in line with the observations of Higgins et al who reported improvement of oral candidiasis in response to ruxolitinib and rescue of IL-17 production caused by unopposed interferon release, normalized Th1 and Tfh cell differentiation, and improved Th17 cell development both in vitro and in vivo.

### Key messages
- A STAT1<sup>E545K</sup> GOF mutation mediated Th1/Tc1 skewing, Th17 cell suppression, and an exaggerated Tfh cell response.
- The JAK inhibitor ruxolitinib mitigated STAT1 hyperphosphorylation, normalized Th1 and Tfh cell differentiation, and improved Th17 cell development both in vitro and in vivo.

### REFERENCES


FIG E1. Hemoglobin and platelet count in response to pharmacotherapy. Graph depicts absolute reticulocyte count in $10^3$ cells per microliter (gray curve) and absolute neutrophil count in cells per microliter (black curve) in response to changes in steroid dose, as well as therapy with ATG, the IL-1 receptor antagonist anakinra, cyclosporine, and ruxolitinib. Timing of packed red blood cell transfusions is indicated in dark gray. The prednisone dose is expressed in milligrams per kilogram body weight.
**FIG E2.** 

*STAT1*<sup>T385M</sup> mutation in patient 2 leads to hyperphosphorylation GOF. A, Phospho-STAT1 (P-STAT1) expression in CD4<sup>+</sup> T cells stimulated with IFN-β and IFN-γ in the *STAT1*<sup>T385M</sup> patient (patient 2) and control subjects. B, Dose-response curve of STAT1 phosphorylation induced with IFN-β and IFN-γ in CD4<sup>+</sup> T cells of patient 2 and control subjects. C, Dephosphorylation kinetics of phospho-STAT1 in response to deprivation of IFN-β and IFN-γ in CD4<sup>+</sup> T cells represented as absolute mean fluorescence intensity (MFI; top) and normalized to maximum expression before deprivation (bottom). D, Phospho-STAT1 expression on IFN-β stimulation in CD4<sup>+</sup> T cells of patient 2 and control subject treated in vitro with ruxolitinib (red curve) and tofacitinib (blue curve) or vehicle (dimethyl sulfoxide, black curve). Plain gray corresponds to unstimulated cells. E, Phospho-STAT1 and phospho-STAT3 MFI expressed as percentage of maximum vehicle-treated control CD4<sup>+</sup> T cells shown in Fig E2, D, in response to increasing concentrations of ruxolitinib (red curve) and tofacitinib (blue curve).